Does Diarrhea Cause Weight Loss on GLP-1s? Calorie-Loss vs Real Fat Loss Distinction

TL;DR — what is actually causing your weight loss

If you are on a GLP-1 medication (semaglutide / Wegovy, tirzepatide / Zepbound) and have diarrhea, and you are losing weight, here is the short answer: the weight loss is real. Diarrhea causes temporary fluid loss that can drop the scale by 1–3 lbs during an acute episode. That fluid comes back when the episode resolves. The sustained weight loss documented in STEP-1 (−14.9% at Week 68, PMID 33567185) and SURMOUNT-1 (−20.9% at Week 72, PMID 35658024) is confirmed fat-mass reduction, verified by dual-energy X-ray absorptiometry (DXA) in body-composition substudies of both trials. The GLP-1 mechanism that drives fat loss is appetite suppression and reduced caloric intake — not diarrhea. Patients who have no diarrhea lose the same fat mass as those who do. Severe or persistent diarrhea is a clinical warning sign, not a sign the drug is working better.

The two mechanisms: appetite suppression vs fluid/gut-content loss

GLP-1 weight loss: the FDA-label mechanism

The Wegovy (semaglutide) US Prescribing Information Section 12.1 describes the mechanism of action verbatim:

“Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Animal studies show that semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.”

Source: WEGOVY US Prescribing Information, Section 12.1 Mechanism of Action, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Novo Nordisk Inc. Verified 2026-05-10.

The Section 12.2 Pharmacodynamics entry elaborates:

“Semaglutide lowers body weight with greater fat mass loss than lean mass loss. Semaglutide decreases calorie intake. The effects are likely mediated by affecting appetite. Semaglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner … Semaglutide delays gastric emptying.”

Source: WEGOVY US Prescribing Information, Section 12.2 Pharmacodynamics, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b. Verified 2026-05-10.

The Zepbound (tirzepatide) Section 12.1 similarly states:

“Tirzepatide is a GIP receptor and GLP-1 receptor agonist … GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation.”

Source: ZEPBOUND US Prescribing Information, Section 12.1 Mechanism of Action, DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, Eli Lilly and Company. Verified 2026-05-10.

And Zepbound Section 12.2:

“Tirzepatide lowers body weight with greater fat mass loss than lean mass loss. Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite … Tirzepatide delays gastric emptying.”

Source: ZEPBOUND US Prescribing Information, Section 12.2 Pharmacodynamics, DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. Verified 2026-05-10.

Diarrhea weight changes: how this is different

Diarrhea causes weight reduction through two mechanisms that are entirely separate from the GLP-1 fat-loss pathway:

• Fluid loss. Each liter of fluid lost via diarrhea weighs approximately 2.2 lbs (1 kg). Mild diarrhea (2–4 loose stools/day for 1–3 days) typically produces 0.5–2 L of excess fluid loss. This translates to 1–4 lbs on the scale. This weight returns fully when the patient rehydrates.
• Reduced gut content. Food, water, and stool in the GI tract together contribute 2–5 lbs to body weight under normal conditions. During GI illness, transit accelerates and gut content is transiently reduced. This also reverses on recovery.

Neither mechanism involves fat oxidation. The scale number goes down during a diarrhea episode and goes back up when normal eating and hydration resumes. This is why patients sometimes feel like they “gained weight” after diarrhea resolves — they did not gain fat; they rehydrated.

STEP-1 and SURMOUNT-1 body composition data: it is mostly fat

SURMOUNT-1 DXA substudy: 75% of weight lost was fat mass

Look et al. (2025) conducted a pre-specified DXA substudy of SURMOUNT-1 (PMID 39996356) in 160 participants from the full trial (n=2,539). Participants underwent dual-energy X-ray absorptiometry at baseline and Week 72. The results are specific and quantified:

“The change in body weight, fat mass and lean mass from baseline to Week 72 was −21.3%, −33.9% and −10.9% with tirzepatide and −5.3%, −8.2% and −2.6% with placebo, respectively (p < 0.001 for all comparisons). Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.”

Source: Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(5):2720-2729. PMID 39996356. Verified 2026-05-10.

In plain terms: tirzepatide-treated participants reduced their fat mass by 33.9% over 72 weeks. This is an objectively large fat-mass reduction, measured by radiology (DXA), not by scale weight alone. Fluid shifts from diarrhea episodes cannot explain a 33.9% fat-mass reduction that persists at Week 72 and shows up on DXA.

Semaglutide STEP program: fat mass reductions confirmed by DXA

O'Neil and Rubino (2022) reviewed body composition findings across the STEP trial program (PMID 36691307). A subgroup in one STEP trial underwent DXA at baseline and end of study. The published finding: reductions in total fat mass were greater with semaglutide 2.4 mg versus placebo. This body-composition finding is consistent with the Section 12.2 Pharmacodynamics statement that semaglutide “lowers body weight with greater fat mass loss than lean mass loss” — language that reflects the DXA substudy data.

Wegovy Section 14.2: the 14.9% result, verbatim

The Wegovy prescribing information Section 14.2 (Weight Reduction and Long-term Maintenance Studies in Adults) documents the primary efficacy result for Study 2 (which corresponds to STEP-1, PMID 33567185):

“Table 8. Changes in Body Weight at Week 68 in Studies 2, 3, and 4 with WEGOVY 2.4 mg Injection — Study 2 (Obesity or overweight with comorbidity): PLACEBO N=655, % change from baseline (LSMean): −2.4. WEGOVY Injection N=1,306, % change from baseline (LSMean): −14.9. % difference from placebo (LSMean) (95% CI): −12.4 (−13.3; −11.6).”

Source: WEGOVY US Prescribing Information, Section 14.2, Table 8, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b. Verified 2026-05-10.

This −14.9% is the drug-treated group mean at Week 68 of a randomized, double-blind, placebo-controlled trial. Placebo patients also had some early fluid loss; the drug-attributable delta is −12.4 percentage points. No transient diarrhea episode explains a −12.4% delta maintained over 68 weeks in a controlled trial.

Zepbound Section 14: the 20.9% result, verbatim

The Zepbound US Prescribing Information Section 14 (Clinical Studies) Table 2 reports for SURMOUNT-1 (PMID 35658024):

“Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight — Study 1: Placebo N=643, % Change from baseline: −3.1. ZEPBOUND 5 mg N=630, % Change: −15.0. ZEPBOUND 10 mg N=636, % Change: −19.5. ZEPBOUND 15 mg N=630, % Change: −20.9.”

Source: ZEPBOUND US Prescribing Information, Section 14, Table 2, DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. Verified 2026-05-10.

Acute diarrhea fluid loss: how much weight does it actually represent?

This is the practical question patients often have: “I had a rough 24 hours. Is the 4 lbs I lost this week real?”

To quantify it conservatively, using fluid-physiology principles:

• Typical GLP-1-related diarrhea (mild, short): 2–4 loose stools per day for 1–3 days, excess fluid loss approximately 0.5–1.5 L. Scale impact: 1–3 lbs. Fully reversible on rehydration.
• Moderate diarrhea (5–8 stools/day for 2–4 days): Excess fluid loss 2–4 L. Scale impact: 4–9 lbs. This is the level at which dehydration becomes clinically significant. The Wegovy FDA label warns explicitly about this range.
• Severe diarrhea (>8 stools/day or inability to maintain hydration): Fluid loss can exceed 5–8 L in acute presentations. Scale impact: 10+ lbs. This is a medical emergency. Contact your prescriber immediately.

In clinical practice, most GLP-1 patients experience mild GI side effects concentrated in the first 1–2 weeks after each dose escalation. The Wegovy Section 6.1 adverse-reactions table reports diarrhea in 30% of patients on 2.4 mg vs 16% on placebo. The Zepbound Table 1 reports 19% at 5 mg, 21% at 10 mg, and 23% at 15 mg vs 8% on placebo. Most of these events are mild-to-moderate in severity.

Key point: the 1–3 lb fluid-loss range is small relative to the 14–21% total body weight changes documented over 68–72 weeks. The drug’s fat-loss effect dwarfs any transient fluid effect.

Week 1–4: why early weight loss feels dramatic

Many patients report losing 5–10 lbs in the first 2–4 weeks of a GLP-1, sometimes more than in later months. This experience is real, and it has a physiological explanation that involves both fluid and early fat loss.

Glycogen and water loss

When caloric intake drops sharply — which happens quickly on a GLP-1 due to appetite suppression and delayed gastric emptying — the body draws on glycogen stores in the liver and muscle. Each gram of glycogen is stored with approximately 3–4 grams of water. A moderate glycogen depletion of 300–400 g releases 900–1,600 g of water alongside it. This is 2–3.5 lbs of scale weight lost within the first week, before any meaningful fat burning has occurred at scale. This is a universal feature of caloric restriction, not specific to GLP-1s.

Reduced gut content

GLP-1s suppress appetite and delay gastric emptying. This means less food is consumed and food stays in the stomach longer. The practical result is that total gut content (food in transit plus water) is reduced by 1–3 lbs compared to a full-fed state. This is a one-time reduction at the start of treatment that does not compound over time; it is a single step down, not ongoing loss.

Early fat loss starts immediately

Fat loss begins from the first week of a sustained caloric deficit. It is slower to accumulate on the scale than glycogen-water loss, but it is real from day one. The STEP-1 trial weight curve (reflected in Wegovy Section 14.2) shows the steepest rate of weight change in the first 16–20 weeks — corresponding with the initial escalation period when appetite suppression is building. The Zepbound label similarly documents that weight reduction was observed from the beginning of treatment.

The practical takeaway: the dramatic early weight loss is a combination of (1) glycogen-water release, (2) reduced gut content, and (3) early fat loss. None of this early loss is “fake.” The glycogen-water component is transient and will plateau, but the fat loss component continues as long as caloric deficit is maintained. Diarrhea may add 1–3 lbs to this early number, but it is a small fraction of the effect.

Will the weight come back when diarrhea resolves?

This is the most common patient concern, and the answer requires distinguishing two different types of weight:

Fluid weight: yes, it comes back

The 1–3 lbs of fluid lost during a diarrhea episode will return when you rehydrate normally. This is physiologically expected and not a setback. Your body requires a certain level of total body water to function. When you lose it through diarrhea, you experience increased thirst; when you drink, that water is retained. A patient who loses 3 lbs during a diarrhea episode and then rehydrates will see the scale return to the pre-episode weight. This is normal and healthy.

Fat loss from caloric restriction: it stays

The fat mass reduced by sustained caloric deficit on a GLP-1 does not return when diarrhea resolves. Fat cells that have shrunk through lipolysis do not re-inflate because you rehydrated. As long as you continue the GLP-1 medication at therapeutic dose and maintain the caloric intake pattern the drug produces through appetite suppression, fat loss continues regardless of GI side-effect status.

The Wegovy label documents this separation clearly: weight loss continued in STEP-1 through Week 68 in patients who maintained the drug. The fat-loss curve does not track GI symptoms — it tracks the duration and depth of caloric restriction.

What happens when the drug is stopped

Weight regain is documented when GLP-1 medications are discontinued. The Wegovy withdrawal trial (Study 5 referenced in Section 14.2) showed that patients who stopped semaglutide after weight loss regained most of their weight by the end of the observation period. This is not related to diarrhea; it is related to the restoration of appetite once the drug’s central nervous system effects are removed. This is a separate pharmacology question from the diarrhea-mechanism question.

Severe diarrhea = faster weight loss? Why this is a danger sign

Social media forums occasionally feature posts suggesting that severe GI symptoms mean “the drug is working hard.” This framing is clinically incorrect and potentially dangerous. Severe diarrhea while on a GLP-1 is a warning sign, not a feature.

The Wegovy prescribing information is explicit about this risk. Section 5.5 states verbatim:

“There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation of WEGOVY.”

Source: WEGOVY US Prescribing Information, Section 5.5 Acute Kidney Injury Due to Volume Depletion, DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b. Verified 2026-05-10.

The Zepbound label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) contains a parallel warning in Section 5.3. Both labels also instruct patients through the Patient Counseling Information section: “Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.”

The dangers of severe GLP-1-associated diarrhea include:

• Acute kidney injury (AKI). Volume depletion reduces renal perfusion. The FDA has received postmarketing AKI reports linked to GLP-1 GI adverse reactions, some requiring hemodialysis.
• Electrolyte imbalances. Diarrhea depletes sodium, potassium, magnesium, and bicarbonate. Hypokalemia (low potassium) can cause muscle weakness and cardiac arrhythmia.
• Hypoglycemia risk in patients on concurrent medications. Reduced food intake combined with fluid depletion can amplify hypoglycemia risk in patients also taking sulfonylureas or insulin.
• Orthostatic hypotension. Volume depletion causes blood pressure to drop on standing. The Zepbound label Section 6.1 Table 1 includes hypotension as an adverse reaction.

Severe diarrhea — defined as more than 6–8 loose stools per day, diarrhea lasting more than 48 hours without improvement, or any diarrhea accompanied by fever, bloody stool, severe abdominal cramping, or inability to keep fluids down — requires urgent prescriber contact. This is not a situation to manage with Imodium and continue the current dose.

DXA scans and body composition tracking: how to know what you are losing

If you want to verify that your weight loss is fat and not fluid, body composition measurement is the most objective approach. Options range in accuracy and cost:

• DXA (gold standard). Dual-energy X-ray absorptiometry separates fat mass, lean mass, and bone mineral density. This is the method used in SURMOUNT-1 (PMID 39996356) and the STEP body-composition substudy (PMID 36691307). Available at academic medical centers and some outpatient imaging facilities. Cost: $50–$150, often not covered by insurance for non-clinical indications.
• Bioelectrical impedance (BIA). Consumer smart scales and clinical BIA devices estimate body composition by measuring resistance to electrical current. Less accurate than DXA, highly sensitive to hydration status — which is particularly problematic during GI illness when fluid status fluctuates. BIA readings taken during or immediately after a diarrhea episode are not reliable.
• Waist circumference. A tape measure is free and tracks visceral fat reduction, which is one of the clinically meaningful outcomes of GLP-1 treatment. The SURMOUNT-1 substudy found significant waist circumference reduction alongside fat-mass reduction.
• Progress photos and clothing fit. Low-tech but informative. Fat loss changes body shape in ways that fluid shifts do not. If clothes are progressively looser over 8–12 weeks, that is fat loss.

If you are concerned that your scale weight is primarily reflecting fluid rather than fat, the most reliable way to verify is a DXA scan at baseline and again at 3 or 6 months. The SURMOUNT-1 DXA protocol measured at Week 72 for a clear endpoint; you do not need to wait that long to see meaningful fat-mass changes.

When to contact your prescriber about diarrhea on a GLP-1

Most GLP-1-associated diarrhea is mild, resolves within 2–4 weeks at each stable dose, and does not require stopping the medication. The following are clinical thresholds that require prescriber contact:

• Diarrhea lasting more than 7 days at a stable dose without improvement. This is beyond the expected adaptation window.
• More than 6–8 loose stools per day. This volume produces clinically significant fluid and electrolyte loss.
• Blood in stool (red or black, tarry stool). This is not a GLP-1 adverse reaction and requires evaluation for other GI pathology.
• Fever above 38°C / 101°F accompanying diarrhea. Suggests infectious gastroenteritis, which should be evaluated independently.
• Inability to maintain fluid intake. If nausea and diarrhea together prevent keeping fluids down for more than 24 hours, call your prescriber. This is the scenario most associated with acute kidney injury in postmarketing reports (Wegovy Section 5.5).
• Dark urine, significantly reduced urination, or dizziness on standing. Signs of significant dehydration. You may need intravenous fluids.
• Severe abdominal pain in the upper abdomen or radiating to the back. Could indicate acute pancreatitis, which is a separate FDA-labeled warning (Wegovy Section 5.2, Zepbound Section 5.2) that requires immediate evaluation and drug discontinuation if confirmed.

Your prescriber may recommend dose de-escalation (stepping back to the prior dose), an extended titration pause, or temporary suspension of the medication while GI symptoms are evaluated. Do not adjust the dose yourself without guidance.

The “Ozempic weight loss is fake” social-media narrative

A recurring claim in online forums and some social media content suggests that GLP-1 weight loss is primarily water weight, that it “all comes back,” or that the dramatic results shown in clinical trials are not real fat loss. The clinical trial record directly contradicts this:

• Trial primary endpoint is body weight, not fluid status. STEP-1 and SURMOUNT-1 measured percent change in total body weight at Week 68 and Week 72 respectively in randomized, double-blind, placebo-controlled trials. Placebo patients are the comparator for fluid shifts, which both groups experience equally.
• DXA confirms fat mass loss. The SURMOUNT-1 DXA substudy (PMID 39996356) directly measured fat mass at Week 72: −33.9% fat mass reduction vs −8.2% placebo. This cannot be explained by fluid loss.
• The drug-attributable delta is fat loss. Wegovy −14.9% vs placebo −2.4% = a drug-attributable −12.4% change. Both groups have fluid dynamics; the difference is the drug’s effect.
• Visceral fat and waist circumference data are consistent. Tirzepatide-treated patients had consistent waist circumference reductions across the SURMOUNT-1 substudy, a structural fat-distribution change that fluid loss does not produce.

The claim that “all the weight comes back” reflects the real finding that weight regains when the drug is stopped. This is pharmacologically expected — the appetite-suppression mechanism requires ongoing drug exposure. It does not mean the weight lost was not fat. Patients who stopped semaglutide in the withdrawal trial regained weight over the following months. This represents the return of appetite-driven caloric intake, not the “unmasking” of prior fluid retention.

What to tell your prescriber

If you are experiencing diarrhea on a GLP-1 and are unsure about your weight-loss progress, consider bringing the following to your next visit:

• Frequency and severity of diarrhea episodes (stools per day, duration, presence of blood or fever).
• Hydration status — are you able to drink 2–3 L of fluids daily? Do you have dark urine?
• Weight trajectory over the past 4–8 weeks(not just the past few days during or after a GI episode).
• Whether GI symptoms are improving at your current dose or worsening. If diarrhea is not improving after 3–4 weeks at a stable dose, your prescriber may recommend a titration pause.
• Any concurrent medications that could interact — particularly NSAIDs (which can worsen renal function in volume-depleted patients), ACE inhibitors, or diuretics.

Do not interpret diarrhea as evidence that the drug is or is not working. The primary signal of GLP-1 efficacy is sustained weight loss over 8–12 weeks, reduced appetite, and (for patients with T2D) improved glycemic control. GI side effects are a tolerability issue to manage, not a progress metric to maximize.

Frequently asked questions

Is my weight loss on a GLP-1 real, or is it just diarrhea?

Your weight loss is real. The Wegovy FDA label documents −14.9% mean body weight at Week 68 vs −2.4% placebo in STEP-1 (PMID 33567185). DXA body-composition data from the SURMOUNT-1 substudy (PMID 39996356) confirmed −33.9% fat mass reduction at Week 72 with tirzepatide. GLP-1 diarrhea causes 1–3 lbs of temporary fluid loss that returns when the episode resolves; it is a side effect, not a weight-loss mechanism.

How much weight does diarrhea cause you to lose on a GLP-1?

Mild diarrhea (2–4 loose stools per day for 1–3 days) produces approximately 1–3 lbs of fluid-loss scale reduction. Moderate episodes can produce 4–9 lbs. This weight returns when you rehydrate normally. It is not fat loss and does not represent additional treatment progress.

Will the weight come back when my diarrhea stops?

The fluid weight (1–3 lbs) will come back when you rehydrate. Fat-mass reduction driven by GLP-1 appetite suppression does not reverse when diarrhea resolves — as long as you continue the medication. The Wegovy withdrawal trial showed weight regain after the drug was stopped, not after GI symptoms resolved.

Does diarrhea cause faster weight loss on Ozempic or Wegovy?

Diarrhea makes the scale number drop faster in the short term due to fluid loss. It does not cause faster fat burning. The GLP-1 fat-loss mechanism is appetite suppression; patients with no diarrhea lose the same fat as patients with diarrhea. Severe diarrhea is a clinical warning sign (acute kidney injury risk per Wegovy Section 5.5), not a positive efficacy signal.

Why did I lose so much weight in week 1–4 of my GLP-1?

Early weight loss combines three effects: (1) glycogen-water release as caloric intake drops sharply (2–4 lbs in week 1); (2) reduced gut content from delayed gastric emptying and lower food intake (1–3 lbs); and (3) early fat loss from sustained caloric deficit. None of this is fake. The glycogen-water component plateaus after the first week; fat loss continues.

Does the Wegovy or Zepbound label mention fluid loss from diarrhea?

Yes. Wegovy Section 5.5 warns verbatim that postmarketing acute kidney injury reports “occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.” Zepbound contains a parallel warning in Section 5.3. Both labels instruct patients to drink fluids to reduce dehydration risk.

Is the 14.9% Wegovy weight loss real or just fluid?

Real fat loss. The −14.9% result in STEP-1 was measured at Week 68 vs a −2.4% placebo group. The drug-attributable delta of −12.4% is confirmed fat-mass loss: the O'Neil and Rubino STEP body-composition analysis (PMID 36691307) confirmed that DXA-measured total fat mass reductions were greater with semaglutide vs placebo.

Should I be glad I have diarrhea because it means I am losing weight?

No. Diarrhea is a listed adverse reaction on both Wegovy and Zepbound FDA labels, not a desired treatment mechanism. It does not increase fat burning. Patients without diarrhea lose the same fat. Severe or persistent diarrhea is a reason to call your prescriber because of the acute kidney injury and electrolyte imbalance risks documented in both labels.

Related articles

• Tirzepatide diarrhea: onset, mechanism, and management — the companion side-effect deep-dive covering the full dose-by-dose FDA label rates from SURMOUNT-1, the enteric-nervous-system mechanism, kidney injury warnings, and evidence-based management strategies for diarrhea on Zepbound or Mounjaro.
• GLP-1 fatigue: onset, mechanism, and management — why semaglutide and tirzepatide cause fatigue, the five biological pathways, verbatim FDA-label hypoglycemia warnings, and management strategies for tiredness on a GLP-1.
• GLP-1 side effects: questions answered with FDA-label evidence — the comprehensive Q&A hub covering headaches, sulfur burps, brain fog, body odor, libido, insomnia, acne, cold intolerance, and taste changes on semaglutide and tirzepatide.
• Tirzepatide headaches: frequency, mechanism, and when to call your doctor — covers Zepbound dose-by-dose headache rates from SURMOUNT-1, dehydration as the primary mechanism, OTC analgesic safety on tirzepatide, and emergency warning signs.
• Creatine on GLP-1: lean mass preservation, hydration, and combined use evidence — the ~25% lean-mass share of GLP-1 weight loss documented by the SURMOUNT-1 DXA substudy (PMID 39996356) raises the practical question of whether creatine supplementation helps. This companion covers the ISSN creatine evidence base, FDA Section 7 labels for Wegovy and Zepbound, the hydration interplay with GLP-1 GI side effects, loading vs maintenance dosing on GLP-1, and kidney safety.

This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs with FDA-labeled risks. Contact your prescriber for guidance on managing GI side effects, dose adjustments, or any symptoms you are concerned about. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations.